Current and Future Roles of PARP Inhibitors in Ovarian Cancer
Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-med
The following article features coverage from the Chemotherapy Foundation Symposium (CFS) in New York, NY. Click here to read more of Cancer Therapy Advisor's conference coverage. |
An oral presentation delivered by Susana M. Campos, MD, MPH, at the 35thAnnual Chemotherapy Foundation Symposium in New York reviewed current literature assessing the use of poly(ADP-ribose) polymerase (PARP) inhibitors among patients with ovarian cancer.1
No hay comentarios:
Publicar un comentario